| Real-world treatment patterns in patients with metastatic castration-resistant prostate cancer in Greece: The PROSPECT study M Liontos, E Bournakis, A Bournakis, E Kostouros, V Zolota, ... Clinical Genitourinary Cancer, 102170, 2024 | | 2024 |
| Improving the efficacy of immunotherapy in patients with advanced or metastatic urothelial carcinoma: a new role for tyrosine kinase inhibitors in the treatment paradigm? R Zakopoulou, M Kyrkasiadou, A Bamias AME Clinical Trials Review 2, 2024 | | 2024 |
| Final Results from SAUL, a Single-arm International Study of Atezolizumab in Unselected Patients with Pretreated Locally Advanced/Metastatic Urinary Tract Carcinoma CN Sternberg, Y Loriot, E Choy, D Castellano, F Lopez-Rios, GL Banna, ... European Urology Focus, 2024 | | 2024 |
| Characterization of complete responders to nivolumab+ gemcitabine-cisplatin vs gemcitabine-cisplatin alone and patients with lymph node–only metastatic urothelial carcinoma … MD Galsky, GP Sonpavde, T Powles, M Claps, M Burotto, M Schenker, ... Journal of Clinical Oncology 42 (16_suppl), 4509-4509, 2024 | | 2024 |
| Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study F Massari, M Santoni, H Takeshita, Y Okada, JC Tapia, U Basso, ... Cancer Immunology, Immunotherapy 73 (6), 1-13, 2024 | 2 | 2024 |
| Real-World Impact of Upfront Cytoreductive Nephrectomy in Metastatic Non-Clear Cell Renal Cell Carcinoma Treated with First-Line Immunotherapy Combinations or Tyrosine Kinase … O Fiala, S Buti, A Bamias, F Massari, R Pichler, M Maruzzo, E Grande, ... Targeted Oncology, 1-13, 2024 | | 2024 |
| PD34-11 NIVOLUMAB PLUS GEMCITABINE-CISPLATIN VERSUS GEMCITABINE-CISPLATIN ALONE IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE OR METASTATIC UROTHELIAL CARCINOMA: RESULTS … G Sonpavde, MS van der Heijden, T Powles, A Necchi, M Burotto, ... Journal of Urology 211 (5S), e723, 2024 | | 2024 |
| Chemotherapy response score as a predictor of survival in ovarian cancer patients I Rodolakis, M Liontos, V Pergialiotis, D Haidopoulos, M Kaparelou, ... European Journal of Obstetrics & Gynecology and Reproductive Biology 296 …, 2024 | | 2024 |
| Lenvatinib plus pembrolizumab versus sunitinib in first-line treatment of advanced renal cell carcinoma: final prespecified overall survival analysis of CLEAR, a phase III study RJ Motzer, C Porta, M Eto, T Powles, V Grünwald, TE Hutson, B Alekseev, ... Journal of Clinical Oncology 42 (11), 1222-1228, 2024 | 15 | 2024 |
| Systemic immune-inflammation index in patients treated with first-line immune combinations for metastatic renal cell carcinoma: insights from the ARON-1 study FSM Monteiro, O Fiala, F Massari, ZW Myint, J Kopecky, J Kucharz, ... Clinical Genitourinary Cancer 22 (2), 305-314. e3, 2024 | 2 | 2024 |
| Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients with metastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1) M Santoni, G Roviello, E Grande, U Giorgi, O Fiala, E Seront, ... | | 2024 |
| Comprehensive 3DCRT Hypofractionated Radiotherapy Schedule for Localized Prostate Adenocarcinoma in the Era of IMRT: Dosimetric and Endoscopic Analysis A Kougioumtzopoulou, N Syrigos, A Zygogianni, I Georgakopoulos, ... Cancers 16 (6), 1192, 2024 | 1 | 2024 |
| Intravesical administration of Durvalumab to patients with high risk non muscle invasive bladder cancer who experience BCG failure. Final results from a phase II study by the … C Fragkoulis, A Bamias, N Gavalas, K Tzannis, E Fragkiadis, A Pinitas, ... European Urology 85, S1716, 2024 | | 2024 |
| Immunomodulatory effects and improved outcomes with cisplatin-versus carboplatin-based chemotherapy plus atezolizumab in urothelial cancer MD Galsky, X Guan, D Rishipathak, AS Rapaport, HM Shehata, ... Cell Reports Medicine 5 (2), 2024 | 8 | 2024 |
| Real-world outcome of patients with advanced renal cell carcinoma and intermediate-or poor-risk international metastatic renal cell carcinoma database consortium criteria … M Santoni, S Buti, ZW Myint, M Maruzzo, R Iacovelli, M Pichler, J Kopecky, ... European urology oncology 7 (1), 102-111, 2024 | 11 | 2024 |
| Pembrolizumab plus enfortumab vedotin in urothelial cancer M Santoni, H Takeshita, F Massari, A Bamias, L Cerbone, O Fiala, ... Nature Reviews Urology, 1-2, 2024 | 1 | 2024 |
| Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial AO Siefker-Radtke, N Matsubara, SH Park, RA Huddart, EF Burgess, ... Annals of Oncology 35 (1), 107-117, 2024 | 29 | 2024 |
| Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised … A Bamias, ID Davis, MD Galsky, JÁ Arranz, E Kikuchi, E Grande, ... The Lancet Oncology 25 (1), 46-61, 2024 | 9 | 2024 |
| Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis … E Grande, JÁ Arranz, M De Santis, A Bamias, E Kikuchi, XG Del Muro, ... The Lancet Oncology 25 (1), 29-45, 2024 | 12 | 2024 |
| Overall Survival by Response to First-line Induction Treatment with Atezolizumab plus Platinum-based Chemotherapy or Placebo plus Platinum-based Chemotherapy for Metastatic … E Grande, A Bamias, MD Galsky, E Kikuchi, ID Davis, JÁ Arranz, ... European Urology Open Science 58, 28-36, 2023 | | 2023 |
